MRI-Targeted Prostate Fusion Biopsy: What Are We Missing outside the Target? Implications for Treatment Planning
Current Oncology · 22.07.2024 · 31 (7) · 4133-4140
DOI: 10.3390/curroncol31070308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 22.07.2024. Verfasst von Marco Oderda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Torino, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Image-Guided Biopsy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
This study aimed to evaluate the added diagnostic value of systematic biopsies (SBx) after magnetic resonance imaging (MRI)-targeted biopsies (TBx) and the presence of prostate cancer (PCa) outside MRI targets, in a prospective, contemporary, multicentric series of fusion biopsy patients.
Methods
We collected data on 962 consecutive patients who underwent fusion biopsy between 2022 and 2024. Prostate cancer was considered clinically significant (csPCa) in the case of grade ≥ 2. Median test and Fisher exact chi-square tests were used. To identify predictors of out-field positivity, univariate and multivariable logistic regression analyses were performed.
Results
Prostate cancer and csPCa were detected by TBx only in 56% and 50%, respectively, and by SBx only in 55% and 45%, respectively (p < 0.001). Prostate cancer and csPCa were diagnosed by TBx in 100 (10%) and 82 (8%) SBx-negative cases and by SBx in 86 (9%) and 54 (6%) TBx-negative cases (p < 0.001). Tumors outside MRI targets were found in 213 (33%) cases in the same lobe and 208 (32%) in the contralateral lobe, most of them being csPCa. Predictors of out-field contralateral PCa were positive DRE (HR 1.50, p 0.03), PSA density ≥ 0.15 (HR 2.20, p < 0.001), and PI-RADS score 5 (HR 2.04, p 0.01).
Conclusions
Both TBx and SBx identify a non-negligible proportion of csPCa when the other modality is negative. SBx after TBx should always be considered given the risk of missing other csPCa foci within the prostate, especially in patients with positive DRE, PSA density ≥ 0.15, and PIRADS 5 lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Torino, Italy.
- Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, 1070 Brussels, Belgium.
- Division of Radiology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Torino, Italy.
- Department of Urology, Centre Hospitalier Universitaire Namur-Godinne, UCLouvain, 5530 Yvoir, Belgium.
- Urology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.
ORCID-Profile: Marco Oderda
Zitieren
APA
Oderda, M., Dematteis, A., Calleris, G., Diamand, R., Gatti, M., Marra, G., Adans-Dester, G., Al Salhi, Y., Pastore, A., Faletti, R., & Gontero, P. (2024). MRI-Targeted Prostate Fusion Biopsy: What Are We Missing outside the Target? Implications for Treatment Planning. Current Oncology, 31(7), 4133-4140. https://doi.org/10.3390/curroncol31070308
Vancouver
Oderda M, Dematteis A, Calleris G, Diamand R, Gatti M, Marra G, et al. MRI-Targeted Prostate Fusion Biopsy: What Are We Missing outside the Target? Implications for Treatment Planning. Current Oncology. 2024;31(7):4133-4140. doi:10.3390/curroncol31070308
BibTeX
@article{Oderda2024,
author = {Oderda, Marco and Dematteis, Alessandro and Calleris, Giorgio and Diamand, Romain and Gatti, Marco and Marra, Giancarlo and Adans-Dester, Gilles and Al Salhi, Yazan and Pastore, Antonio and Faletti, Riccardo and Gontero, Paolo},
title = {MRI-Targeted Prostate Fusion Biopsy: What Are We Missing outside the Target? Implications for Treatment Planning},
journal = {Current Oncology},
year = {2024},
volume = {31},
number = {7},
pages = {4133--4140},
doi = {10.3390/curroncol31070308}
}
EUVIMED